Compare ArcelorMittal SA (MT) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ArcelorMittal SA vs BIO-TECHNE Corp — how do they compare? ArcelorMittal SA trades at $65 (market cap $50.01B), while BIO-TECHNE Corp trades at $71.63 (market cap $11.16B). The key difference: ArcelorMittal SA is far larger — about 4.5× BIO-TECHNE Corp's market cap, and ArcelorMittal SA pays the higher dividend (0.91%). Which is the better fit depends on your goals.
| MT | TECH | |
|---|---|---|
Market Cap | $50.01B | $11.16B |
Sector | Basic Materials | Health |
52-Week High | $71.65 | $72.12 |
52-Week Low | $30.39 | $43.31 |
Enterprise Value | $59.33B | $11.24B |
Dividend Yield | 0.91% | 0.45% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ArcelorMittal (MT) trades at $65.80, down 0.98% today, with a bullish technical outlook supported by moving averages. The stock shows strong earnings momentum, beating estimates for three consecutive quarters, and maintains a reasonable valuation with a P/E of 17.24 and P/S of 0.81. Recent corporate developments include ongoing share buybacks and a strategic AI collaboration with AWS to enhance operational efficiency.
The outlook for MT is cautiously optimistic, driven by earnings strength and cost initiatives, but faces risks from cyclical steel demand and high capital expenditures. Analyst sentiment is mixed with 50% buy ratings, suggesting potential upside if operational improvements continue, though investors should monitor global economic conditions impacting steel prices.
Bio-Techne (TECH) trades at $71.63, down 0.68% on the day, near its all-time high following a $73 per share acquisition offer from Merck KGaA. The stock shows bullish technical signals with strong moving averages and ADX trends. Fundamentally, the company reported mixed quarterly earnings but maintains solid gross margins of 64.96%. Recent news is dominated by the proposed $11.3 billion buyout, driving significant investor interest and legal scrutiny over the transaction's fairness.
The outlook is heavily influenced by the pending acquisition, with upside capped near the $73 offer price. Risks include shareholder litigation and regulatory approval delays. Analyst consensus is split evenly between Buy and Hold, reflecting uncertainty around deal completion. The stock presents a potential arbitrage opportunity if the acquisition proceeds, but carries event risk if the transaction fails.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ArcelorMittal SA
ArcelorMittal SA is involved in the steel industry. The company's operating segments include NAFTA
Read more on MT →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
